Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T16:52:49.077Z.
Calculation as of: 2026-10-06T16:52:49.077Z.
Quote observation: 2026-10-06T16:46:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: ca628ff6f55b6345e2cefca22780bd34dfabddebf8a5c62bf0c86d2d29f40561
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Market Cap
$11.46M
EBITDA Yield
N/A
TTM Avg
41.52%
3Y Avg
41.52%
5Y Avg
41.52%
Market Cap
$12.37M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Phio Pharmaceuticals Corp. (PHIO) | $11.61M | N/A | N/A | N/A | N/A |
| Kiora Pharmaceuticals, Inc. (KPRX)vs › | $11.46M | N/A | 41.52% | 41.52% | 41.52% |
| Biofrontera Inc. (BFRI)vs › | $11.45M | N/A | N/A | N/A | N/A |
| Pluri Inc. (PLUR)vs › | $11.33M | N/A | 0.09% | 0.09% | 0.09% |
| BioVie Inc. (BIVI)vs › | $11.12M | N/A | N/A | N/A | N/A |
| IRIDEX Corporation (IRIX)vs › | $12.12M | N/A | 0.96% | 2.71% | 3.80% |
| Cerenome, Inc. (CNSY)vs › | $10.94M | N/A | N/A | N/A | N/A |
| Adial Pharmaceuticals, Inc. (ADIL)vs › | $11.11M | N/A | N/A | N/A | N/A |
| Bullfrog AI Holdings, Inc. Common Stock (BFRG)vs › | $12.37M | N/A | N/A | N/A | N/A |
| Lantern Pharma Inc. (LTRN)vs › | $12.44M | N/A | N/A | N/A | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
